Supporting Diversity in Clinical Trial Recruitment

Our unique relationships with 100+ traditional and non-traditional recruitment partners enable us to connect sponsors with diverse populations that may otherwise be unreachable using conventional approaches. Here’s how the Citeline Connect Recruitment Collective partnership network drives study awareness and participation globally.

### Phase II-III Alzheimer’s Disease Trial (ongoing)
- Our unique relationships with 100+ traditional and non-traditional recruitment partners enable us to connect sponsors with diverse populations that may otherwise be unreachable using conventional approaches.
- Here’s how the Citeline Connect Recruitment Collective partnership network drives study awareness and participation globally.
- **Tap into the Citeline network of 100+ recruitment partners to drive study awareness and participation among patient populations representative of the real world.**

#### Recruitment of diverse patients spanned across 19 states
- 34% of Citeline connect qualified referrals in screening identify as a minority
- 7 recruitment partners supported the enrollment of diverse study participants

#### Recruitment of diverse patients spanned across 2 countries
- 5 recruitment partners supported the enrollment of diverse study participants

### Phase II Atopic Dermatitis Trial
- **Oct. 2022 - Feb. 2023**
- 64% of Citeline Connect qualified referrals identify as a minority
- 5 recruitment partners supported the enrollment of diverse study participants

### Phase III CMV Trial (ongoing)
- **Sept. 2022 - present**
- Contributing to 44% of US enrollment; 43% of Citeline Connect qualified referrals identify as a minority
- 15 recruitment partners supported the enrollment of diverse study participants
- Recruitment of diverse patients spanned across 4 countries

### Phase III RSV Trial
- **Sept. 2022 - Dec. 2023**
- 18% conversion rate
- 25,000+ referrals in 4 months with 25% diversity
- 7 recruitment partners supported the enrollment of diverse study participants
- Recruitment of diverse patients spanned across 2 countries

### Phase III COVID-19 Trial
- **Sept. - Oct. 2021**
- Doubled overall enrollment and increased diversity from 24% to 37%
- 14 recruitment partners supported the enrollment of diverse study participants
- Recruitment of diverse patients spanned across 100 sites and 31 states in the US

Top into the Citeline network of 100+ recruitment partners to drive study awareness and participation among patient populations representative of the real world.